Suwinski Rafal, Bankowska-Wozniak Magdalena, Majewski Wojciech, Sowa Anna, Idasiak Adam, Ziolkowska Ewa, Windorbska Wieslawa, Tarnawski Rafal, Skladowski Krzysztof, Maciejewski Boguslaw
Centre of Oncology, Maria-Sklodowska-Curie Memorial Institute, Branch Gliwice, Poland.
Radiother Oncol. 2005 Oct;77(1):58-64. doi: 10.1016/j.radonc.2005.07.007. Epub 2005 Sep 12.
To analyse acute mucosal reactions in patients treated with continuous accelerated postoperative irradiation (p-CAIR) compared to conventionally fractionated postoperative radiotherapy (p-CF).
The patients were randomly assigned to receive 63 Gy in 1.8 Gy fractions 7-days-a-week given over a period of 5 weeks (n=88), or 63 Gy in 1.8 Gy fractions given 5-days-a-week over 7 weeks (n=87). It represents 65% of an overall trial size. Acute mucosal reactions were scored using modified Dische system. Polychotomous logistic regression was used to estimate the influence of the selected variables on maximum grade of mucositis, and percent of the body weight loss during radiotherapy.
The average maximum Dische score and percent of the patients with confluent mucositis were higher in patients treated with p-CAIR, compared to p-CF (13.3 vs. 10.8 and 54 vs. 27%). Polychotomous logistic regression analysis revealed that fractionation scheme and tumour site have significantly influenced maximum Dische score. Tumour site (laryngeal vs. other) had even stronger influence on maximum Dische score than fractionation scheme. The average residual Dische score 8 weeks after radiotherapy was higher in p-CAIR compared to p-CF (2.1 vs. 1.4), and was, most frequently, related to persistent mucosal erythema (70 vs. 57% of pts.). No severe consequential toxicity of radiotherapy was observed, so far, in the trial.
While the incidence, intensity and duration of mucosal reactions was higher in p-CAIR than in p-CF the accelerated treatment can be considered tolerable with respect to acute toxicity. In both arms of the trial slight or moderate mucosal erythema was the most frequent acute side effect, which did not completely subside within 8 weeks after irradiation.
分析与传统分割术后放疗(p-CF)相比,接受持续加速术后放疗(p-CAIR)的患者的急性黏膜反应。
患者被随机分配,一组每周7天、每天接受1.8 Gy分割剂量,共5周,总剂量63 Gy(n = 88);另一组每周5天、每天接受1.8 Gy分割剂量,共7周,总剂量63 Gy(n = 87)。这占整个试验规模的65%。使用改良的迪斯切系统对急性黏膜反应进行评分。采用多分类逻辑回归来估计所选变量对黏膜炎最高分级以及放疗期间体重减轻百分比的影响。
与p-CF相比,接受p-CAIR治疗的患者的平均迪斯切最高评分以及出现融合性黏膜炎的患者百分比更高(分别为13.3对10.8以及54%对27%)。多分类逻辑回归分析显示,分割方案和肿瘤部位对迪斯切最高评分有显著影响。肿瘤部位(喉癌与其他部位)对迪斯切最高评分的影响甚至比分割方案更强。放疗8周后,p-CAIR组的平均迪斯切残余评分高于p-CF组(2.1对1.4),且最常见的是与持续性黏膜红斑有关(分别为70%对57%的患者)。到目前为止,该试验中未观察到放疗的严重后续毒性。
虽然p-CAIR组黏膜反应的发生率、强度和持续时间高于p-CF组,但就急性毒性而言,加速治疗可被认为是可耐受的。在试验的两组中,轻微或中度黏膜红斑是最常见的急性副作用,在放疗后8周内并未完全消退。